Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advances on the study of antituberculotic drugs

( views:277, downloads:264 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES

Issue:: 1

DOI:: 10.3760/cma.j.issn.1674-2397.2010.01.018

Key Word:: 结核;抗结核化合物;Tuberculosis;Antituberculotic compounds

Abstract： @@ 结核病是由结核分枝杆菌(MTB)感染引起的慢性传染病,主要累及肺,是传染病中单一导致死亡人数最多的疾病,也是最常见的与艾滋病相关的机会感染性疾病~([1-2]).MTB可侵入人体全身各脏器,经血源播散至脑、脊髓、肝、肾和肠等组织.结核病多见于免疫功能低下人群,包括HIV感染者,估计每年有800万肺结核新发病例,全世界每年有300万～400万人死于结核病,以发展中国家患者为甚~([3]).

Reference

[1]陈国良,谭国良,孙平华.抗结核药物的研究与开发[J].2004,(12).
[2]夏志伟,高三友,王友谊,等.利福喷丁对结核病高危人群的保护作用研究[J].2005,(5).
[3]符志军.氟喹诺酮类药物抗结核作用的评价[J].2006,(3).
[4]么鸿雁,施侣元.我国结核病耐药状况及其变化趋势的Meta分析[J].2003,(4).
[5]王陇德.中国结核病控制现状及展望[J].2006,(8).
[6]Copp,B.R.,Pearce,A.N..Natural product growth inhibitors of Mycobacterium tuberculosis[J].2007,24(2).
[7]Lee Jia,Lori Coward,Gregory S.Gorman,etc.Pharmacoproteomic Effects of Isoniazid,Ethambutol,and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv[J].2005,315(2).
[8]Gallicano K,Peloquin C,Burman WJ.Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.[J].2001,40(5).
[9]Shampa, Khasnobis,Vincent E, Escuyer,Delphi, Chatterjee.Emerging therapeutic targets in tuberculosis: post-genomic era.[J].2002,6(1).
[10].Social leverage of intellectual property: road to the development of better therapy for tuberculosis.[J].2009,4(2).
[11]Basso LA,Vasconcelos IB,Moreira IS,etc.Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents.[J].2007,8(3).
[12]Dick, van Soolingen,Kristin, Kremer.[Findings and ongoing research in the molecular epidemiology of tuberculosis].[J].2009,84(2).
[13]Lacy Daniels,Clifton E. Barry III,Siew Siew Pang,etc.Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis[J].2006,103(2).
[14]Prasad B,Singh S,Bhutani H.Study of the interaction between rifapentine and isoniazid under acid conditions.[J].2006,41(4).
[15]Gevers T,Van-Den-Berg J,Andries K,etc.Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.[J].2008,52(10).
[16]Cantarero L,Andries K,Lenaerts AJ,etc.Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.[J].2007,51(9).
[17]Rothstein DM,Suchland RJ,Xia M,etc.Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae.[J].2008,61(8).
[18]Mdluli K,Spigelman M.Novel targets for tuberculosis drug discovery.[J].2006,6(5).
[19]Palacios JJ,Aznar F,Garcia AB,etc.New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.[J].2006,16(22).
[20]Herrera L.,Valverde A.,Saez-Nieto JA.,etc.Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature[J].2003,21(5).
[21]O'Connor TM,Barry PJ.Novel agents in the management of Mycobacterium tuberculosis disease.[J].2007,14(18).
[22]Papadopoulou MV,McNeil MR,Bloomer WD.NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis[J].2007,29(6).
[23]Jones KD,Hesketh T,Yudkin J.Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern.[J].2008,102(3).
[24]Shenai S,Rodrigues C,Mehta A.Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex.[J].2009,13(1).
[25]Moreira IS,de Sousa EH,Santos DS,etc.Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.[J].2006,12(19).
[26]Ram VJ,Kumari S.Advances in molecular targets and chemotherapy of tuberculosis.[J].2004,40(6).